BIOSIMILARS: MARKET ACCESS AND MARKET PENETRATION - A COMPARISON OF FRANCE AND GERMANY

被引：0
|
作者：
Freiberg, M. [1 ]
Schwarz, R. [1 ]
Khoury, C. [2 ]
机构：
[1] Quintiles Commercial Germany GmbH, Mannheim, Germany
[2] Quintiles Advisory Serv, St Ouen, France
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.553
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP16
引用
收藏
页码：A442 / A442
页数：1
相关论文
共 50 条
  • [21] BIOSIMILARS IN THE EUROPEAN MARKET
    Lindner, L.
    Gimenez, E.
    Rovira, J.
    Espin, J.
    Olry, A.
    Leticia, G.
    VALUE IN HEALTH, 2011, 14 (07) : A338 - A338
  • [22] Navigating the Biosimilars Market
    Sheppard, Alan
    BIOPHARM INTERNATIONAL, 2011, 24 (09) : S12 - S12
  • [23] Biosimilars in the European market
    Rovira, Joan
    Lindner, Leandro
    Gimenez, Emmanuel
    Espin, Jaime
    Olry de labry, Antonio
    Garcia, Leticia
    GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL, 2013, 2 (01): : 30 - 35
  • [24] EXPLAINING THE DISPARITIES OF MARKET ACCESS FOR GLIFLOZINS IN FRANCE, SPAIN, GERMANY AND THE UNITED-KINGDOM
    Bodaghi, C.
    Benque, E.
    Troubat, A.
    VALUE IN HEALTH, 2018, 21 : S134 - S134
  • [25] IDENTIFYING CURRENT ATMP MARKET ACCESS CHALLENGES AND STRATEGIES IN FRANCE, GERMANY, ITALY, AND SPAIN
    Lucion, D.
    Ghinelli, F.
    Buxton, J.
    Wright, J.
    Steeds, C.
    Hall, S.
    Buchholz, P.
    VALUE IN HEALTH, 2023, 26 (12) : S369 - S370
  • [26] RESISTANCE TO OR SUPPORT OF BIOSIMILARS' MARKET PENETRATION? A SYSTEMATIC REVIEW OF EUROPEAN STAKEHOLDERS' BEHAVIOURS
    Braoudaki, E.
    Barton, P.
    VALUE IN HEALTH, 2019, 22 : S428 - S428
  • [27] CHANGES IN THE PRICES OF REFERENCE BIOTECHNOLOGY PRODUCTS BY THE PENETRATION OF BIOSIMILARS INTO THE TURKISH PHARMACEUTICAL MARKET
    Tuna, E.
    Kockaya, G.
    VALUE IN HEALTH, 2015, 18 (07) : A535 - A535
  • [28] MARKET ACCESS OF ATMPS IN FRANCE: CHALLENGES AND OPPORTUNITIES
    Le Mao, J.
    Parant, P.
    Villemur, L.
    VALUE IN HEALTH, 2023, 26 (12) : S389 - S389
  • [29] MARKET ACCESS OF DRUGS IN FRANCE: EVOLUTION OR REVOLUTION?
    Remuzat, C.
    Toumi, M.
    VALUE IN HEALTH, 2012, 15 (07) : A304 - A304
  • [30] What role for real-world evidence in market access of biosimilars?
    Simoens, Steven
    Lockhart, Catherine M.
    Courmier, Delphine F.
    FRONTIERS IN PHARMACOLOGY, 2025, 16
12345